Market Research Logo

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

Summary

Renal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market is currently dominated by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in particular, but it will experience dramatic changes over the forecast period as patents expire and promising new therapies enter the market. A large share of the RCC market is currently dominated by a few large companies, but they will struggle to retain these shares as they are joined by new entrants. One of these new entrants, Opdivo, is expected to have the largest market share by 2023. The different lines of treatment will offer up different battlegrounds and niches for companies, large and small, to compete for. The battle for the first-line of therapy is expected to be fierce, with three programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1)-containing combination therapies backed by large companies lining up to compete. Out of this competition, new standards of care are expected to emerge for the different lines of treatment. There will also be a number of unmet needs still remaining at the end of the forecast period, and with that, the opportunity for pipeline drugs to carve out a niche in the RCC space.

Highlights

Key Questions Answered

  • The RCC market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of RCC market?
  • The late-stage RCC pipeline has therapies targeting different lines of therapy. Which drugs will have the biggest impact in each RCC setting? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • Current therapies used to treat RCC include tyrosine kinase inhibitors and mTOR inhibitors. What will be the impact of the patent expiry of the current standard of care? How will the advent of new therapies change the drug treatment landscape for RCC? How will new drug combinations change the treatment paradigm of RCC? What are the key drivers and barriers to this change?
Key Findings
  • The main drivers of the growth of the RCC market will be the launch of Opdivo in second-line setting and PD-1 modulator combinations in the first-line setting. GlobalData forecasts significant patient uptake for Opdivo, which will supersede tyrosine kinase inhibitors and mTOR inhibitors to become the SoC in second-line setting.
  • The approval of immunotherapy in monotherapy or in combination with other agents will partially fulfil key unmet needs in the RCC space: however, many of these unmet needs will still remain even after these agents are launched.
  • Another driver of the RCC market is the increasing incidence of RCC cases within the 8MM. The biggest constrainer of the RCC market is the launch of generics of tyrosine kinase inhibitors currently established as standard of care in most markets.
Scope
  • Overview of RCC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized RCC therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the RCC therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global RCC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global RCC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RCC therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global RCC therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Clinical Staging
3.3 Symptoms
3.4 Prognostic Models
3.5 Potential Biomarkers
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 Incidence
4.3.2 Survival Rates for RCC - 8MM
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods for RCC Diagnosed Incident Cases
4.4.4 Forecast Assumptions and Methods for RCC Five-Year Diagnosed Prevalent Cases
4.4.5 Forecast Assumptions and Methods for RCC by Clinical Stage at Diagnosis
4.5 Epidemiological Forecast of RCC (2013-2023)
4.5.1 Diagnosed Incident Cases of RCC
4.5.2 Age-Specific Diagnosed Incident Cases of RCC
4.5.3 Sex-Specific Diagnosed Incident Cases of RCC
4.5.4 Age-Standardized Diagnosed Incidence of RCC
4.5.5 Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis
4.5.6 Five-Year Diagnosed Prevalent Cases of RCC
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Screening and Diagnosis
5.1.2 Surgical Management of RCC
5.1.3 Treatment Guidelines and Leading Prescribed Drugs
5.1.4 Clinical Practice
5.2 US
5.2.1 Diagnosis and Surgical Management
5.2.2 Clinical Practice (Drug Treatment)
5.3 France
5.3.1 Diagnosis and Surgical Management
5.3.2 Clinical Practice (Drug Treatment)
5.4 Germany
5.4.1 Diagnosis and Surgical Management
5.4.2 Clinical Practice (Drug Treatment)
5.5 Italy
5.5.1 Diagnosis and Surgical Management
5.5.2 Clinical Practice (Drug Treatment)
5.6 Spain
5.6.1 Diagnosis and Surgical Management
5.6.2 Clinical Practice (Drug Treatment)
5.7 UK
5.7.1 Diagnosis and Surgical Management
5.7.2 Clinical Practice (Drug Treatment)
5.8 Japan
5.8.1 Diagnosis and Surgical Management
5.8.2 Clinical Practice (Drug Treatment)
5.9 China
5.9.1 Diagnosis and Surgical Management
5.9.2 Clinical Practice (Drug Treatment)
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles - Major Brands
6.2.1 Sutent (sunitinib)
6.2.2 Nexavar (sorafenib)
6.2.3 Votrient (pazopanib)
6.2.4 Avastin (bevacizumab)
6.2.5 Torisel (temsirolimus)
6.2.6 Inlyta (axitinib)
6.2.7 Afinitor (everolimus)
6.2.8 Interferon-alfa
6.2.9 Interleukin-2
6.2.10 Tarceva (erlotinib)
7 Unmet Needs and Opportunities
7.1 Overview
7.2 Challenge the Resistance to Metastatic RCC Treatments With New Targeted Agents Improving the Survival of Metastatic RCC Patients
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Drugs With Improved Tolerability Profiles
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 More Efficacious Therapies for the Treatment of Unfavorable Risk Metastatic RCC
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Targeted Therapies for Non-Clear Cell RCC
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 Novel Adjuvant Therapies for Non-Metastatic RCC
7.6.1 Unmet need
7.6.2 Gap Analysis
7.6.3 Opportunity
7.7 Biomarkers
7.7.1 Overview
7.7.2 Gap Analysis
7.7.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Promising Drugs in Clinical Development
8.2.1 Opdivo (nivolumab) and Yervoy (ipilimumab)
8.2.2 Atezolizumab
8.2.3 Cometriq (cabozantinib)
8.2.4 IMA901
8.2.5 AGS-003 (rocapuldencel-t)
8.2.6 Tivozanib
8.2.7 Lenvima (lenvatinib)
8.2.8 Avelumab
9 Promising Approaches in Early-Stage Development
9.1 Keytruda (pembrolizumab)
9.1.1 Overview
9.2 Dalantercept (ACE-041)
9.2.1 Overview
9.3 Archexin (RX-021)
9.3.1 Overview
9.4 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Pfizer
10.3.2 Novartis
10.3.3 Bayer
10.3.4 Roche
10.3.5 Bristol-Myers Squibb
10.3.6 Merck & Co.
10.3.7 Exelixis
10.3.8 Eisai
10.3.9 AVEO Oncology
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Forecasting Methodology
12.4.1 Diagnosed RCC Patients
12.4.2 Percent Drug-Treated Patients
12.4.3 Drugs Included in Each Therapeutic Class
12.4.4 Launch and Patent Expiration Dates
12.4.5 General Pricing Assumptions
12.4.6 Average Body Weight and Surface Area Across the 8MM
12.4.7 General Forecast Assumptions
12.4.8 Individual Drug Assumptions
12.4.9 Generic Erosion
12.4.10 Pricing of Pipeline Agents
12.5 Primary Research - KOLs Interviewed for This Report
12.6 Primary Research - High-Prescribers Surveyed for this Report
12.7 About the Authors
12.7.1 Author
12.7.2 Epidemiologist
12.7.3 Therapy Director
12.7.4 Global Director of Therapy Analysis and Epidemiology
12.7.5 Global Head of Healthcare
12.8 About GlobalData
12.9 Disclaimer
1.1 List of Tables
Table 1: Classifications of RCC
Table 2: TNM and Staging Classification System for RCC
Table 3: Symptoms of RCC
Table 4: Risk Factors and Comorbidities for RCC
Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages ≥20 Years, 1993-2007
Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages ≥20 Years, 1993-2007
Table 7: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages ≥20 Years, 1993-2007
Table 8: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages ≥20 Years, 1993-2007
Table 9: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2007
Table 10: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases
Table 11: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases
Table 12: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis
Table 13: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
Table 14: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013
Table 15: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N (Row %), 2013
Table 16: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
Table 17: Treatment Guidelines for RCC
Table 18: Most Prescribed Drugs for RCC by Class in the 8MM
Table 19: Country Profile - US
Table 20: Country Profile - France
Table 21: Country Profile - Germany
Table 22: Country Profile - Italy
Table 23: Country Profile - Spain
Table 24: Country Profile - UK
Table 25: Country Profile - Japan
Table 26: Country Profile - China
Table 27: Leading Treatments for RCC, 2015
Table 28: Product Profile - Sutent (sunitinib)
Table 29: Results of the Trial Comparing Sutent Versus IFN-alfa
Table 30: Summary of AEs from the Trial of Sutent Versus IFN-alfa
Table 31: Sutent SWOT Analysis, 2014
Table 32: Global Sales Forecasts ($m) for Sutent 2013-2023
Table 33: Product Profile - Nexavar (sorafenib)
Table 34: Results of the Trial Comparing Nexavar Versus Placebo
Table 35: Summary of AEs from the Trial of Nexavar versus Placebo
Table 36: Nexavar SWOT Analysis, 2014
Table 37: Global Sales Forecast ($m) for Nexavar, 2013-2023
Table 38: Product Profile - Votrient (pazopanib)
Table 39: Results of the Trial Comparing Votrient Versus Placebo
Table 40: Summary of the Results of the Trials Comparing Votrient Versus Sutent
Table 41: Summary of AEs from the Trial of Votrient Versus Sutent
Table 42: Votrient SWOT Analysis, 2014
Table 43: Global Sales Forecast ($m) for Votrient, 2013-2023
Table 44: Product Profile - Avastin (bevacizumab)
Table 45: Results of the Trial Comparing Avastin + IFN-alfa Versus IFN-alfa + Placebo
Table 46: Summary of AEs from the Trial of Avastin + IFN-alfa Versus IFN-alfa + placebo
Table 47: Avastin SWOT Analysis, 2014
Table 48: Global Sales Forecasts ($m) for Avastin, 2013-2023
Table 49: Product Profile - Torisel (temsirolimus)
Table 50: Results of the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa
Table 51: Summary of AEs from the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa
Table 52: Torisel SWOT Analysis, 2014
Table 53: Global Sales Forecasts ($m) for Torisel, 2013-2023
Table 54: Product Profile - Inlyta (axitinib)
Table 55: Results of the Trial Comparing Inlyta Versus Nexavar
Table 56: Summary of AEs from the Trial Comparing Inlyta Versus Nexavar
Table 57: Inlyta SWOT Analysis, 2014
Table 58: Global Sales Forecasts ($m) for Inlyta, 2013-2023
Table 59: Product Profile - Afinitor (everolimus)
Table 60: Results of the Record-1 Trial Comparing Afinitor Versus Placebo
Table 61: Summary of AEs from the Trial Comparing Afinitor Versus Placebo
Table 62: Afinitor SWOT Analysis
Table 63: Global Sales Forecasts ($m) for Afinitor, 2013-2023
Table 64: Results of the Trial Comparing IFN-alfa Versus IFN-alfa + vinblastine
Table 65: Summary of AEs from the Trial of IFN-alfa
Table 66: Results of the Trial Comparing High-Dose IL-2 Versus IL-2 + IFN-alfa
Table 67: Summary of AEs from the High-Dose IL-2 Versus IL-2 + IFN-alfa Trial
Table 68: Selected placebo-controlled, randomized adjuvant RCC trials
Table 69: Comparison of Therapeutic Classes in Development for RCC, 2016
Table 70: Product Profile - Opdivo (nivolumab)
Table 71: Product Profile - Yervoy (imilimumab)
Table 72: Efficacy of Opdivo in the CheckMate 025 Trial
Table 73: Efficacy of Opdivo + Yervoy, Opdivo + Stutent, and Opdivo + Votrient
Table 74: Safety of Opdivo and Afinitor from the CheckMate 025 Trial
Table 75: Safety Profile of Opdivo + Yervoy, Opdivo + Sutent, and Opdivo + Votrient
Table 76: Opdivo (monotherapy or combination with Yervoy) SWOT Analysis, 2016
Table 77: Global Sales Forecasts ($M) for Opdivo, 2013-2023
Table 78: Product Profile - Atezolizumab
Table 79: Efficacy of Atezolizumab
Table 80: Efficacy of Atezolizumab + Avastin combination therapy
Table 81: Safety of Atezolizumab in Phase Ib Study
Table 82: Atezolizumab SWOT Analysis, 2016
Table 83: Global Sales Forecasts ($M) for Atezolizumab, 2013-2023
Table 84: Product Profile - Cometriq (cabozantinib)
Table 85: Efficacy of Cometriq in the Phase III METEOR Trial
Table 86: Safety of Cometriq
Table 87: Cometriq SWOT Analysis, 2016
Table 88: Global Sales Forecasts ($M) for Cometriq, 2013-2023
Table 89: Product Profile - IMA901
Table 90: Efficacy of IMA901 in the Phase III IMPRINT Trial
Table 91: Product Profile - AGS-003
Table 92: AGS-003 SWOT Analysis, 2016
Table 93: Global Sales Forecasts ($M) for AGS-003, 2013-2023
Table 94: Product Profile - Tivozanib
Table 95: Efficacy of Tivozanib
Table 96: Safety of Tivozanib
Table 97: Safety profile of Tivozanib over time
Table 98: Tivozanib SWOT Analysis, 2016
Table 99: Global Sales Forecasts ($M) for Tivozanib, 2013-2023
Table 100: Product Profile - Lenvima (lenvatinib)
Table 101: Efficacy of Lenvima
Table 102: Lenvima SWOT Analysis, 2016
Table 103: Global Sales Forecasts ($M) for Lenvima, 2013-2023
Table 104: Product Profile - Avelumab
Table 105: Avelumab (in combination with Inlyta) SWOT Analysis, 2016
Table 106: Global Sales Forecasts ($M) for Avelumab, 2013-2023
Table 107: Drug Candidates in Early Development, 2016
Table 108: Key Companies in the RCC Market in the 8MM, 2013-2023
Table 109: Pfizer’s RCC Portfolio Assessment, 2016
Table 110: Novartis’ RCC Portfolio Assessment, 2016
Table 111: Bayer’s RCC Portfolio Assessment, 2016
Table 112: Roche’s RCC Portfolio Assessment, 2016
Table 113: BMS’ RCC Portfolio Assessment, 2016
Table 114: Merck & Co.’s RCC Portfolio Assessment, 2016
Table 115: Exelixis’ RCC Portfolio Assessment, 2016
Table 116: Eisai RCC Portfolio Assessment, 2016
Table 117: AVEO Oncology’s RCC Portfolio Assessment, 2016
Table 118: Argos Therapeutics’ RCC Portfolio Assessment, 2016
Table 119: Sales Forecasts ($m) for Renal Cell Carcinoma in the Global Markets, 2013-2023
Table 120: RCC Market Drivers and Barriers, 2013-2023
Table 121: Sales Forecasts ($m) for Renal Cell Carcinoma in the United States, 2013-2023
Table 122: Key Events Impacting Sales for RCC in the US, 2016
Table 123: US RCC Market Drivers and Barriers, 2016
Table 124: Sales Forecasts ($m) for Renal Cell Carcinoma in 5EU, 2013-2023
Table 125: Key Events Impacting Sales for RCC in 5EU, 2016
Table 126: 5EU RCC Market Drivers and Barriers, 2016
Table 127: Sales Forecasts ($m) for Renal Cell Carcinoma in Japan, 2013-2023
Table 128: Key Events Impacting Sales for RCC in Japan, 2016
Table 129: Japan RCC Market - Drivers and Barriers, 2016
Table 130: Sales Forecasts ($m) for Renal Cell Carcinoma in China, 2013-2023
Table 131: Key Events Impacting Sales for RCC in China, 2016
Table 132: China RCC Market - Drivers and Barriers, 2016
Table 133: RCC Incidence, 2013-2023
Table 134: RCC, Key Launch Dates
Table 135: RCC, Key Patent Expiries
Table 136: Average Body Weight and Surface Area Across the 8MM
Table 137: Average Cost of Therapy of Sutent
Table 138: Average Cost of Therapy of Votrient
Table 139: Average Cost of Therapy of Nexavar
Table 140: Average Cost of Therapy of Avastin
Table 141: Average Cost of Therapy of Inlyta
Table 142: Average Cost of Therapy of Torisel
Table 143: Average Cost of Therapy of Afinitor
Table 144: Average Cost of Therapy of Opdivo
Table 145: Average Cost of Therapy of Yervoy + Opdivo
Table 146: Average Cost of Therapy of Atezolizumab
Table 147: Average Cost of Therapy of Avelumab
Table 148: Average Cost of Therapy of Cometriq
Table 149: Average Cost of Therapy of Lenvima
Table 150: Average Cost of Therapy of tivozanib
Table 151: Average Cost of Therapy of AGS-003
Table 152: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013
Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N, 2013
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013
Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages ≥20 Years, N, 2013
Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
Figure 7: Treatment Algorithm for RCC
Figure 8: RCC - Phase III Pipeline, 2013-2023
Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in RCC, 2013-2023
Figure 10: Opdivo’s Development in RCC
Figure 11: Clinical and Commercial Positioning of Opdivo
Figure 12: Atezolizumab’s Development in RCC
Figure 13: Clinical and Commercial Positioning of Atezolizumab
Figure 14: Cometriq’s Development in RCC
Figure 15: Clinical and Commercial Positioning of Cometriq
Figure 16: AGS-003’s Development in RCC
Figure 17: Clinical and Commercial Positioning of AGS-003
Figure 18: Tivozanib’s Development in RCC
Figure 19: Clinical and Commercial Positioning of Tivozanib
Figure 20: Lenvima’s Development in RCC
Figure 21: Clinical and Commercial Positioning of Lenvima
Figure 22: Avelumab’s Development in RCC
Figure 23: Clinical and Commercial Positioning of Avelumab
Figure 24: Global Sales of Branded Products for aRCC by Company, 2013-2023
Figure 25: Company Portfolio Gap Analysis in RCC, 2013-2023
Figure 26: Pfizer SWOT Analysis in RCC, 2014
Figure 27: Novartis SWOT Analysis in RCC, 2014
Figure 28: Bayer SWOT Analysis in RCC, 2014
Figure 29: Roche SWOT Analysis in RCC, 2014
Figure 30: Bristol-Myers Squibb SWOT Analysis in RCC, 2014
Figure 31: Merck & Co SWOT Analysis in RCC, 2014
Figure 32: Exelexis SWOT Analysis in RCC, 2014
Figure 33: Eisai SWOT Analysis in RCC, 2014
Figure 34: AVEO Oncology SWOT Analysis in RCC, 2014
Figure 35: Argos Therapeutics SWOT Analysis in RCC, 2014
Figure 36: Global Sales for aRCC by Region, 2013-2023
Figure 37: Global sales for aRCC by Class, 2013-2023
Figure 38: Global Sales for aRCC by Brand, 2013-2023
Figure 39: Sales for aRCC in the US by Class, 2013-2023
Figure 40: Sales for aRCC in the US by Brand, 2013-2023
Figure 41: Sales for aRCC in the 5EU by Class, 2013-2023
Figure 42: Sales for aRCC in 5EU by Brand, 2013-2023
Figure 43: Sales for aRCC in the Japan by Class, 2013-2023
Figure 44: Sales for aRCC in Japan by Brand, 2013-2023
Figure 45: Sales for aRCC in the China by Class, 2013-2023
Figure 46: Sales for aRCC in China by Brand, 2013-2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report